title: Use of fluoroquinolones in patients with chronic hepatitis C virus-induced liver failure.
abstract: Fluroquinolone antibiotics have been reported to have antiviral properties against RNA viruses, including hepatitis C virus (HCV). In the present study, five patients with advanced liver disease secondary to chronic HCV received 500 mg daily of oral ciprofloxacin for 30 days. Serum HCV-RNA levels and liver enzyme abnormalities remained largely unchanged. Thus, the role of fluoroquinolones as antiviral agents for chronic HCV in patients with advanced liver disease appears to be limited.
authors.affiliation: Liver Diseases Unit, University of Manitoba, Winnipeg, Canada.
authors.forename: H
authors.initials: H
authors.lastname: Kojima
authors.forename: K D E
authors.initials: KD
authors.lastname: Kaita
authors.forename: K
authors.initials: K
authors.lastname: Hawkins
authors.forename: J
authors.initials: J
authors.lastname: Uhanova
authors.forename: G Y
authors.initials: GY
authors.lastname: Minuk
mesh_terms: D000410:Alanine Transaminase / Q000378:metabolism; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D004311:Double-Blind Method; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000821:virology; D006801:Humans; D008099:Liver / Q000378:metabolism; D017093:Liver Failure / Q000188:drug therapy* / Q000821:virology*; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D012367:RNA, Viral; D002939:Ciprofloxacin; D000410:Alanine Transaminase